The dataset shows a clear leader with 317 records, well ahead of the fifth-place assignee at 53 and the tenth at 34. The leading ten organisations together account for 781 of the 1,039 records in scope, or 75.2%, so filing activity is heavily concentrated rather than evenly spread across the field. A new entrant should expect to be filing into a space where a handful of large biologics companies already hold dense, overlapping claim positions.

Filing peaked at 113 records in 2018 and has eased since, with the most recent complete comparison showing a -35% move from 43 records in 2021 to 28 in 2024. Because patent publication typically lags filing by around 18 months, the 2025 and 2026 figures in any dataset are still incomplete and should not be read as proof the field has gone quiet. The safer read is that activity has cooled from an unusually active 2017-2018 period rather than that interest has disappeared.

Classification data shows C12N (microorganisms and genetic engineering) touching 98.3% of records, while C12M (bioreactor apparatus) sits at 14.2% and C12Q (enzyme and DNA testing methods) at just 2.3%. That gap suggests the instrumentation and in-line assay layer that actually triggers a harvest decision — sensors, real-time viability modelling, integrated titer monitoring — is comparatively open relative to the crowded cell-engineering core. Filers looking for less contested claim space should look at that hardware and assay layer rather than the biology itself.

US20190194602A1 claims a genetically modified mammalian cell culture that expresses a neublastin antibody polypeptide, along with the antibody product made by that culture. It anchors its claims to a specific engineered cell line and molecule rather than to a general harvest-timing method, so it primarily blocks close variants of that particular antibody-producing culture rather than harvest-decision logic broadly. Anyone drafting a process claim around viability or titer signals should still check it, but it is not a blanket barrier to harvest-timing method claims generally.

Co-assignment is uncommon in this landscape: only ten co-assignee pairs appear across the full dataset, and the strongest pairing covers 19 shared records. Most of the largest filers prosecute independently, which means portfolio risk and claim overlap are concentrated within single organisations rather than spread across joint ventures. This matters for freedom-to-operate analysis because it narrows the number of parties a new filer needs to clear against for any given large portfolio.